CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast
Main Authors: Di Cosimo, Serena, Porcu, Luca, Cardoso, Fatima
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2020
Assuntos:
Short Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7758367/
https://ncbi.nlm.nih.gov/pubmed/33352521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.12.006
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares